DOCSLIB.ORG

Application of Various Chemotherapeutic Agents in Experimental Bovine Anaplasmosis S.K

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Application of Various Chemotherapeutic Agents in Experimental Bovine Anaplasmosis S.K APPLICATION OF VARIOUS CHEMOTHERAPEUTIC AGENTS IN EXPERIMENTAL BOVINE ANAPLASMOSIS S.K. Sharma, D.P. Banerjee, O.P. Gautam To cite this version: S.K. Sharma, D.P. Banerjee, O.P. Gautam. APPLICATION OF VARIOUS CHEMOTHERAPEUTIC AGENTS IN EXPERIMENTAL BOVINE ANAPLASMOSIS. Annales de Recherches Vétérinaires, INRA Editions, 1977, 8 (3), pp.307-313. hal-00900943 HAL Id: hal-00900943 https://hal.archives-ouvertes.fr/hal-00900943 Submitted on 1 Jan 1977 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. APPLICATION OF VARIOUS CHEMOTHERAPEUTIC AGENTS IN EXPERIMENTAL BOVINE ANAPLASMOSIS S.K. SHARMA, D.P. BANERJEE O.P. GAUTAM Department of Veterinary Medicine, College of Veterinary Sciences, Haryana Agricultural University, Hlssar-125004, Haryana, India ’ Résumé UTILISATION DE DIVERS AGENTS CHIMIOTHERAPEUTIQUES AU COURS DE L’ANAPLAS- MOSE BOVINE EXPERIMENTALE. ― Un essai de traitement a été réalisé avec différents agents ehimiothérapeutiques, sur des cas cliniques ou des porteurs inapparents d’ana- plasmose bovine expérimentale. La Dithiosemicarbazone (associée à l’Oxytétracycline), le Chloramphénicol et la Rolitétracycline ont très efficacement entraîné la guérison clinique et l’élimination des agents pathogènes. L’imidocarb a entraîné la guérison clinique sans supprimer complètement les microorganismes. La Gentamycine resta inefficace. Introduction cyclines inhibit growth of Anaplasma, stu- dies were directed to evaluate these drugs in relation to the elimination of infection Drugs such as oxytetracycline, chlorte- (Brock, Pearson and Kliewer, 1953, 1958; tracycline and tetracycline hydrochloride Foote and Wulf, 1952; Pearson, Brock and have proved useful in treating clinical cases Kliewer, 1957 ; and Splitter and Miller, 1953 of anaplasmosis but these often failed to and Magonigle et al., 1975). These studies eliminate the carrier status. Unless the revealed that tetracyclines would « sterilizes carrier status is eliminated, the source of infections only after the prolonged adminis- infection remains and these animals consti- tration of large quantities. Such prolonged tute a potential danger to other susceptible periods of treatment are impossible in many stock. In recent years, attention has been systems of management and this has ini- focused on the treatment of carrier cases. tiated the search for more efficient drugs , The elimination of the carrier infection is (Kuttler, 1973). particularly important in those herds in which The present paper describes investigations eradication measures are feasible (Wheeler, concerning the effectiveness of several che- 1968). motherapeutic agents against clinical and As soon as it was recognized that tetra- carrier cases of bovine anaplasmosis. Materials and methods Dithiosemicarbazone and Oxysteclin were administered 5 mg/kg each intravenously for 4 doses on alternate days to six animals The chemotherapeutic trial was conducted (three carriers and three clinical cases). on cattle, 6-12 months old, of both sexes, Chlorplon was given 8 mg/kg intramuscularly that were experimentally infected with Ana- once daily subsequently for 5 days to four plasma marginale. Bos indicus and B. indi- animals (two carriers and two clinical cases) cus cross-breds were included in the trial. and for 3 days to three clinical cases. The cross-breds came down with the clinical Reverin was administered intramuscularly form of the disease, whereas, the indigenous 150 mg per animal for 5 consecutive days stock remained as carriers. The following to five animals (three carriers and two clini- drugs were used : cal cases). Garamycin was administered i) Dithiosemicarbazone (356 C61 - Bur- 80 mg per animal intramuscularly daily for roughs Wellcome and Co.) combined with 3 days to three clinical cases. lmizol was Oxytetracycline (Oxysteclin - Squibb). used for investigating its chemotherapeutic ii) Chloramphenicol (Chlorplon - Khandel- and chemoprophylactic properties. For che- wal Laboratories Pvt.Ltd.). motherapy, two doses were given at an inter- iii) Rolitetracycline (Reverin - Hoechst). val of 7 days 5 mg/kg to five cross-bred iv) Gentamicin sulphate (Garamycin - C.E. clinical cases. For chemoprophylaxis, the Fulford, India, Pvt.Ltd.). drug was given intramuscularly 8 mg/kg each v) lmidocarb dipropionate (Imizol - Bur- to four cross-bred animals out of which two roughs Wellcome and Co.). animals were challenged 100 days and the rest two 50 days after the drug administra- of parasitaemia on subinoculation and sple- ’ tion. nectomy. Similar results were obtained in When the treated animals showed no orga- the animals treated with Chloramphenicol nisms on peripheral blood examination they and Rolitetracycline. The drugs were, there- were splenectomized for the recrudescence fore, effective in the clinical as well as of parasitaemia, if any. The blood of such carrier phases of the disease. However, animals that were still free from the infec- Chloramphenicol with 3 doses proved less tion after splenectomy, was subinoculated effective as the treated animals could not to intact healthy animals which were later completely get rid of infection. Gentamicin splenectomized. sulphate was found ineffective. It neither eliminated the organism nor caused a clinical recovery. lmidocarb dipropionate brought a clinical recovery but did not completely Results eliminate the organisms and a rare parasi- ’ taemia (below 1 per cent) persisted in the treated animals. Neither it had any chemo- Dithiosemicarbazone with Oxytetracycline prophylactic activity as all the animals of proved to be very efficacious and the treated the group showed 3-13 per cent parasitaemia animals became completely free of infection on challenge. as judged by the clinical recovery and nega- The effects of the drugs on the course tive blood smear and failure of the treated of the disease and haematological features animal’s blood to elicit the recrudescence are demonstrated in Figures 1, 2, 3, 4 and compared with that of untreated control 1970 ; Kuttler and Zaraza, 1970 ; Roby, Ame- animal (Fig. 5). rault and Spindler, 1968). Roby (1968) was No side effect was observed with any of of the opinion that dithiosemicarbazone eli- the drug used. minates the carrier state in cattle, presuma- bly in a similar manner that the tetracyclines do. The combined therapy of dithiosemi- carbazone and tetracycline has been claimed Discussion by earlier workers to yield superior results than the therapy with either drug (Brown, Wilde and Berger, 1968; Roby, Am4rault and Our results on dithiosemicarbazone are Spindler, 1968 ; Kuttler, 1971 a, b ; Kuttler comparable with that of Brown, Wilde and and Zaraza, 1970; Bedell, 1971). It seems Berger (1968) and Roby, Amerault and Spin- that the joint action of the drugs affords dler (1968). In our hands, dithiosemicarba- both rickettsiastatic and rickettsiacidal zone completely eliminated the carrier sta- actions on A. marginale by exerting a syner- tus and did not show any side effects as gistic or at least an additive effect. observed by Adams and Kuttler (1970). There is no earlier report on the use of Dithiosemicarbazone has recently been des- Chloramphenicol, Rolitetracycline and Gen- cribed as having a specific chemotherapeu- tamicin sulphate against bovine anaplasmo- tic effect on Anaplasma (Barrett et al., 1965 ; sis. Chloramphenicol is a broad-spectrum Kuttler, 1971 a, b. 1972 ; Kuttler and Adams, antibiotic isolated from Streptomyces vene- zuelae. Its antimicrobial spectrum is marked 1973 ; Roby and Mazzola, 1972; McHardy against a wide range of infectious diseases and Simpson, 1974, 1975). On contrary to caused by gram-negative and gram-positive our findings, Roby (1973) mentioned elimi- bacteria, rickettsiae and certain of the large nation of anaplasmosis carrier status by viruses. Intramuscular administration of lmidocarb at 5 mg/kg two times at 7, 14 Chloramphenicol gives a rapid response and 21 days interval. and this drug produces no pain at the site Ours is probably the first attempt to study of injection and has no side effects. Addi- the efficacy of Chloramphenicol and Roli- tionally, the drug has a greater stability - tetracycline in bovine anaplasmosis. A has a life of four years at room tempera- comparatively low cost of these drugs cou- ture. In cases of anaplasmosis which are pled with their dose requirements and high refractory to other broad spectrum anti- margin of safety make them suitable for biotics Chloramphenicol might be useful. anaplasmosis therapy both for clinical reco- Rolitetracycline, unlike other parenteral very and elimination of the carrier status. totracyclines, is stable at a pH which is well tolerated by the tissues and hence there (Accepted for publication, June 1977.) is no irritation or induration around the site of injection. It is very soluble and quickly absorbed. In comparison to other tetra- cyclines, the effect of Rolitetracycline is Acknowledgements prompt besides being useful in eliminating the carrier status of infection with the We are thankful to M/s Burroughs Well- recommended doses. come
Load more

Recommended publications
  • Technical Information
    Technical Information Antibiotic Assay Medium No.1 (Seed Agar) Product Code : DM1003 Application: - Antibiotic Assay Medium No.1 (Seed Agar) is used in the microbiological assay of beta-lactam and other antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 6.000 or detecting faecal coliforms drinking in water waste water, seawater and foods samples by MPN Method. Casein enzymic hydrolysate 4.000 Yeast extract 3.000 Beef extract 1.500 Dextrose 1.000 Agar 15.000 Final pH (at 25°C) 6.6±0.2 **Formula adjusted, standardized to suit performance parameters Principle & Interpretation The potency of an antibiotic can be determined by chemical, physical and biological methods. An assay is performed to determine the ability of an antibiotic to kill or inhibit the growth of living microorganisms. Biological tests offer the most convenient m eans of performing an assay (1), since a reduction in the antimicrobial activity of a specific antibiotic reveals changes that is not usually displayed by chemical methods (2). Antibacterial susceptibility testing may be performed by either dilution (turbidimetric) or diffusion methods. The choice o f methodology is based on many factors, including ease of performance, flexibility and use of automated or semi-automated devices for both identification and susceptibility testing (3). Grove and Randall have elucidated antibiotic assays and media in their comprehensive treatise on antibiotic assays (4). Antibiotic Assay Medium No.1 is used in the microbiological assay of ß-lactam and other antibiotics. These media are prepared according to the specifications detailed in various pharmacopoeias (2-6) and by the FDA (7).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042
    HiMedia Laboratories Technical Data Antibiotic Assay Medium No. 3 (Assay Broth) is used for M042 microbiological assay of antibiotics. Antibiotic Assay Medium No. 3 (Assay Broth) is used for microbiological assay of antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 5.000 Beef extract 1.500 Yeast extract 1.500 Dextrose 1.000 Sodium chloride 3.500 Dipotassium phosphate 3.680 Potassium dihydrogen phosphate 1.320 Final pH ( at 25°C) 7.0±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 17.5 grams in 1000 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Advice:Recommended for the Microbiological assay of Amikacin, Bacitracin, Capreomycin, Chlortetracycline,Chloramphenicol,Cycloserine,Demeclocycline,Dihydrostreptomycin, Doxycycline, Gentamicin, Gramicidin, Kanamycin, Methacycline, Neomycin, Novobiocin, Oxytetracycline, Rolitetracycline, Streptomycin, Tetracycline, Tobramycin, Trolendomycin and Tylosin according to official methods . Principle And Interpretation Antibiotic Assay Medium is used in the performance of antibiotic assays. Grove and Randall have elucidated those antibiotic assays and media in their comprehensive treatise on antibiotic assays (1). Antibiotic Assay Medium No. 3 (Assay Broth) is used in the microbiological assay of different antibiotics in pharmaceutical and food products by the turbidimetric method. Ripperre et al reported that turbidimetric methods for determining the potency of antibiotics are inherently more accurate and more precise than agar diffusion procedures (2). Turbidimetric antibiotic assay is based on the change or inhibition of growth of a test microorganims in a liquid medium containing a uniform concentration of an antibiotic. After incubation of the test organism in the working dilutions of the antibiotics, the amount of growth is determined by measuring the light transmittance using spectrophotometer.
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Of Significant in Vitro Antagonism Between Penicillin, Cephalothin, and Rolitetracycline FRANZ D
    ANTIMICROBIAL AGENTS AND CHEmoTHzRAPY, Nov. 1976, p. 802-808 Vol. 10, No. 5 Copyright © 1976 American Society for Microbiology Printed in U.S.A. Combination of Bacteriostatic and Bactericidal Drugs: Lack of Significant In Vitro Antagonism Between Penicillin, Cephalothin, and Rolitetracycline FRANZ D. DASCHNERI Children Hospital, Division ofAntimicrobial Therapy, University ofMunich, 8 Munich 2, Germany Received for publication 16 April 1976 Although it is generally believed that bactericidal and bacteriostatic drugs should not be combined in vivo, in vitro experiments using the checkerboard dilution technique revealed no antagonism between penicillin/cephalothin and rolitetracycline but rather additive or synergistic activity of either drug combi- nation in 40 to 50% of20 Escherichia coli and 14 Staphylococcus aureus strains. Slight antagonism occurred only between 3 and 8 h after combining penicillin/ cephalothin and rolitetracycline in either bacteriostatic or bactericidal concen- trations, but not after 24 h of incubation, nor was antagonism found with combinations of these drugs in bacteriostatic concentrations. Neither bacterio- static nor bactericidal activity of penicillin/cephalothin and rolitetracycline was inhibited by pretreatment of one E. coli strain with bacteriostatic rolitetracyc- line or bacteriostatic penicillin/cephalothin concentrations. Penicillin and ceph- alothin could exert a bactericidal effect after 2-h exposure of theE. coli strain to bacteriostatic rolitetracycline concentrations. Combined action of subinhibitory penicillin and rolitetracycline concentrations resulted in more pronounced inhi- bition of growth than either drug alone. The higher activity of penicillin/ cephalothin in combination with rolitetracycline on some E. coli and S. aureus strains might be due to a better access of rolitetracycline into bacterial cells whose cell walls have been weakened by cell wall-active, bactericidal drugs.
    [Show full text]
  • Characterization and in Vitro Release Studies of Tetracycline and Rolitetracycline Imobilized on Anionic Collagen Membranes
    Materials Research, Vol. 12, No. 1, 69-74, 2009 © 2009 Characterization and in vitro Release Studies of Tetracycline and Rolitetracycline Imobilized on Anionic Collagen Membranes Gilberto Goissisa*, Maria Helena de Sousab* aDepartamento de Produção, Biotech Biomédica Produtos Médicos e Odontológicos Ltda. Rua Santos Dumont, 800, Vila Celina, 13566-445 São Carlos - SP, Brazil bFaculdade Farmácia, Campus de Jatai, Universidade Federal de Goiás – UFG, Jatai - GO, Brazil Received: June 20, 2008; Revised: January 6, 2009 This work reports the covalent immobilization of tetracycline and rolitetracycline over anionic collagen membranes and the drug release studies as an effort to develop a two stage drug release based on diffusion (fast release) and on the rate of membrane biodegradation (slow release). Independent from casting conditions antibiotics incorporated by dispersion were released in the range from 80 to 100% within 7 hours in concentrations significantly higher than those described for the prevention of bacterial growth. Antibiotic release within this period was predominantly diffusion controlled. Covalent immobilization by a modified azide procedure occurred with preservation of collagen structure independently from pH of casting and reaction conditions. Its expected that anionic collagen membranes with dispersed and covalently bound rolitetracycline or tetracycline, in association with conventional therapy, may significantly reduce membrane induced infections observed post-implantation, one of the major problem associated with periodontal ligaments reconstruction by the Guided Tissue Regeneration procedure. Keywords: antibiotic, immobilization, covalent, release, collagen, membranes 1. Introduction Sustained drug release technology1 is being applied from protein this purpose formulations include tetracycline fibber, doxycycline hormones such as insulin for the treatment of diabetes2 to antibiotics polymer, chlorhexidine chip, minocycline ointment and metronida- for the prevention or minimization of bacterial infection3-5.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Antibiotics and Antibiotic Resistance
    This is a free sample of content from Antibiotics and Antibiotic Resistance. Click here for more information on how to buy the book. Index A Antifolates. See also specific drugs AAC(60)-Ib-cr, 185 novel compounds, 378–379 ACHN-975 overview, 373–374 clinical studies, 163–164 resistance mechanisms medicinal chemistry, 166 sulfamethoxazole, 378 structure, 162 trimethoprim, 374–378 AcrAB-TolC, 180 Apramycin, structure, 230 AcrD, 236 Arbekacin, 237–238 AdeRS, 257 Avibactam, structure, 38 AFN-1252 Azithromycin mechanism of action, 148, 153 resistance, 291, 295 resistance, 153 structure, 272 structure, 149 Aztreonam, structure, 36 AIM-1, 74 Amicoumacin A, 222 Amikacin B indications, 240 BaeSR, 257 structure, 230 BAL30072, 36 synthesis, 4 BB-78495, 162 Aminoglycosides. See also specific drugs BC-3205, 341, 344 historical perspective, 229–230 BC-7013, 341, 344 indications, 239–241 b-Lactamase. See also specific enzymes mechanism of action, 232 classification novel drugs, 237 class A, 67–71 pharmacodynamics, 238–239 class B, 69–74 pharmacokinetics, 238–239 class C, 69, 74 resistance mechanisms class D, 70, 74–77 aminoglycoside-modifying enzymes evolution of antibiotic resistance, 4 acetyltransferases, 233–235 historical perspective, 67 nucleotidyltransferases, 235 inhibitors phosphotransferases, 235 overview, 37–39 efflux-mediated resistance, 236 structures, 38 molecular epidemiology, 236–237 nomenclature, 67 overview, 17, 233 b-Lactams. See also specific classes and antibiotics ribosomal RNA modifications, 235–236 Enterococcus faecium–resistancemechanisms,
    [Show full text]
  • New Classification Framework of Tetracyclines And
    Cornell University Library Arxiv.org/quantitative-biology/biomolecules New Classification Framework and Structure-Activity- Relationship (SAR) of Tetracycline-Structure-Based Drugs Domenico Fuoco, Pharm.D., Ph.D BioTech Consultant; Member of Italian National Order of Chemists and Italian Chemical Society in Rome, Italy By studying the literature about Tetracyclines (TCs), it becomes clearly evident that TCs are very dynamic molecules. In some cases, their structure-activity-relationship (SAR) are known, especially against bacteria, while against other targets, they are virtually unknown. In other diverse yields of research, such as neurology, oncology and virology the utility and activity of the tetracyclines are being discovered and are also emerging as new technological fronts. The first aim of this paper is classify the compounds already used in therapy and prepare the schematic structure in which include the next generation of TCs. The aim of this work is introduce a new framework for the classification of old and new TCs, using a medicinal chemistry approach to the structure of that drugs. A fully documented Structure-Activity-Relationship (SAR) is presented with the analysis data of antibacterial and nonantibacterial (antifungal, antiviral and anticancer) tetracyclines. Lipophilicity of functional groups and conformations interchangeably are determining rules in biological activities of TCs. Upper peripheral modification region Introduction The number of articles published on tetracycline drugs reached the threshold of 50,000 papers since 1948. Over the last 10 years, technological fields are emerging in bacteriology and cellular physiology of eukaryotic cells. However, Lower peripheral non modifiable region chemical mechanisms of tetracyclines are not completely understood as for their action in human cells and to this day, no (Q)SAR model Figure 1.
    [Show full text]
  • Summary Report on Antimicrobials Dispensed in Public Hospitals
    Summary Report on Antimicrobials Dispensed in Public Hospitals Year 2014 - 2016 Infection Control Branch Centre for Health Protection Department of Health October 2019 (Version as at 08 October 2019) Summary Report on Antimicrobial Dispensed CONTENTS in Public Hospitals (2014 - 2016) Contents Executive Summary i 1 Introduction 1 2 Background 1 2.1 Healthcare system of Hong Kong ......................... 2 3 Data Sources and Methodology 2 3.1 Data sources .................................... 2 3.2 Methodology ................................... 3 3.3 Antimicrobial names ............................... 4 4 Results 5 4.1 Overall annual dispensed quantities and percentage changes in all HA services . 5 4.1.1 Five most dispensed antimicrobial groups in all HA services . 5 4.1.2 Ten most dispensed antimicrobials in all HA services . 6 4.2 Overall annual dispensed quantities and percentage changes in HA non-inpatient service ....................................... 8 4.2.1 Five most dispensed antimicrobial groups in HA non-inpatient service . 10 4.2.2 Ten most dispensed antimicrobials in HA non-inpatient service . 10 4.2.3 Antimicrobial dispensed in HA non-inpatient service, stratified by service type ................................ 11 4.3 Overall annual dispensed quantities and percentage changes in HA inpatient service ....................................... 12 4.3.1 Five most dispensed antimicrobial groups in HA inpatient service . 13 4.3.2 Ten most dispensed antimicrobials in HA inpatient service . 14 4.3.3 Ten most dispensed antimicrobials in HA inpatient service, stratified by specialty ................................. 15 4.4 Overall annual dispensed quantities and percentage change of locally-important broad-spectrum antimicrobials in all HA services . 16 4.4.1 Locally-important broad-spectrum antimicrobial dispensed in HA inpatient service, stratified by specialty .
    [Show full text]
  • Effect of Chloramphenicol on a Bioassay Response for the Detection of Tetracycline Residues in Milk
    36 Journal of Food and Drug Analysis, Vol. 17, No. 1, 2009, Pages 36-42 藥物食品分析 第十七卷 第一期 Effect of Chloramphenicol on a Bioassay Response for the Detection of Tetracycline Residues in Milk ORLANDO NAGEL1, MARÍA DE LA LUZ ZAPATA2, JUAN CARLOS BASÍLICO2, JORGE BERTERO1, MARÍA PILAR MOLINA3 AND RAFAEL ALTHAUS1* 1. Cátedra de Biofísica, Departamento de Ciencias Básicas, Universidad Nacional del Litoral, R.P.L. Kreder 2805, 3080 Esperanza, República Argentina. 2. Cátedra de Microbiología, Facultad de Ingeniería Química, Universidad Nacional del Litoral, Santiago del Estero 2826, 3000 Santa Fe, República Argentina. 3. Departamento de Ciencia Animal, Universidad Politécnica de Valencia, Camino de Vera, Valencia, España. (Received: Febuary 4, 2008; Accepted: October 9, 2008) ABSTRACT The tetracyclines are commonly used in veterinary medicine, and yet the residues are not always detected by microbiological inhibitor tests using Geobacillus stearothermophilus subsp. calidolactis C-953 at their Maximum Residue Limit levels. In order to improve the sensitivity of these methods, a bioassay was evaluated to study the effect produced by the incorporation of different chloramphenicol (CAP) concentrations in the culture medium. The specificity and detection limits of six tetracyclines in milk were determined. As the levels of CAP increased, a decrease in specificity, from 97.9% (for 0, 50, 200 and 400 µg/kg of CAP) to 88.0% (for 600 µg/kg of CAP) was observed. The logistic regression model indicates a significant effect of the CAP concentra- tion. However, the tetracycline-CAP interaction was not significant, and thus, a synergetic effect can not be considered between the two antimicrobials, with only a simple sum of their antimicrobial effects.
    [Show full text]